A study of a brain health service found common modifiable dementia risks among people with subjective cognitive decline and linked high p-Tau217 to early neurodegeneration signs.

• Huckfarm Team
• October 3, 2026

A phase II trial found pain relief after 4-Gy radiation for myeloma bone lesions, with few severe side effects and no reported harm to marrow status.

• Huckfarm Team
• October 3, 2026

Gold’s Gym and NASM are partnering on trainer certification, education and career development at Gold’s company-owned clubs.

• Huckfarm Team
• October 2, 2026

The FDA approved AbbVie’s once-daily Parkinson’s pill Juvmo for early symptoms and as an add-on in later disease. U.S. availability is expected in October 2026.

• Huckfarm Team
• October 2, 2026

After years seeking memory testing, Sean Terwilliger was diagnosed with early-onset Alzheimer’s at 60 and says writing helped him find purpose.

• Huckfarm Team
• October 2, 2026